BioSpectrum the business of Bio & Health Sciences ASIA EDITION

JCDC receives human research protection accreditation in India

September 17, 2012 | News | By BioSpectrum Bureau

India's JCDC becomes 7th in Asia to receive AAHRPP accreditation



Bangalore:Ã?Â The Association for the Accreditation of Human Research ProtectionÃ?Â Programs, announced that it has accredited a third organization in India, JehangirÃ?Â Clinical Development Center (JCDC) in Pune, and a second contract research organization, (CRO) Celerion, headquartered in Nebraska.

The accreditations are the latest indication that organizations are embracing AAHRPP's goal ofÃ?Â one set of standards worldwide for CROs, independent institutional review boards, research-intensiveÃ?Â universities, medical colleges, hospitals, and other entities engaged in research involving human participants.

Inroads in critical markets
India is among the fastest growing markets for clinical trials. However, growth has also brought calls for stronger research protections and greater emphasis on research quality. As in the US, organizations increasingly are answering that call by seeking AAHRPP accreditation.

"By earning AAHRPP accreditation, Jehangir Clinical Development Centre has taken the lead inÃ?Â demonstrating a commitment to safe, ethical research," said Dr Marjorie A Speers, AAHRPP president and CEO. "Like its AAHRPP-accredited peers in the United States and India, Jehangir Clinical Development Centre has earned a place among some of the world's mostÃ?Â respected research organizations."

In fact, to attain AAHRPP accreditation, JCDC had to show compliance with both India'sÃ?Â requirements for research protections and US regulations.
Even before attaining AAHRPP accreditation, JCDC had taken steps to differentiate itself fromÃ?Â other entities in India.

"At JCDC, we set up a research center, built the infrastructure, and committed the resourcesÃ?Â necessary for a quality research program," said JCDC CEO, Mr Pathik Divate. "We viewedÃ?Â AAHRPP accreditation as the logical step to take our program to the next level-for researchÃ?Â participant protection, standardization, and quality. We've also sent a message to the rest of the research institutes," he added. "If they're serious about clinical research, they should be thinking about

AAHRPP accreditation."

The accreditation of Celerion's clinical facilities in Lincoln and Neptune represents a similar milestone. Celerion is the second CRO, and the first headquartered in theÃ?Â US, to earn AAHRPP accreditation. CRO accreditations are particularly important because these organizations typically oversee the higher-risk phase 1 clinical trials.

"The AAHRPP accreditation demonstrates the leadership role Celerion has taken to reach theÃ?Â highest standards and protections for human participants in our clinical studies," said Dr SusanÃ?Â Thornton, president and CEO, Celerion. "This accreditation also highlights ourÃ?Â commitment to increased quality and transparency in conducting ethically sound research for ourÃ?Â clients."

Speers praised Celerion for setting an example and raising the bar for research protections amongÃ?Â CROs. "With AAHRPP accreditation, Celerion now offers a level of quality assurance that distinguishesÃ?Â it among CROs and boosts its appeal to research sponsors," she said. "Our hope is thatÃ?Â Celerion's decision has a ripple effect across the research enterprise and that other CROs followÃ?Â suit."

AAHRPP accreditation is available to US and international organizations that conductÃ?Â biomedical, behavioral or social sciences research involving human participants. AAHRPP already has accredited organizations in 46 states, Canada, China, India, Korea and Singapore.